カテゴリー： Market Monitor Global, 世界, 医療/バイオ

血友病治療薬のグローバル市場展望 2023年-2029年：血液製品、遺伝子組み換え製品

◆英語タイトル：Hemophilia Medication Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC14358）

◆商品コード：MMG23DC14358
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月（※2025年版があります。お問い合わせください。）
◆ページ数：115
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の血友病治療薬市場規模と予測を収録しています。・世界の血友病治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の血友病治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の血友病治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血液製品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

血友病治療薬のグローバル主要企業は、Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、血友病治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の血友病治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の血友病治療薬市場：タイプ別市場シェア、2022年
・血液製品、遺伝子組み換え製品

世界の血友病治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の血友病治療薬市場：用途別市場シェア、2022年
・血友病A、血友病B

世界の血友病治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の血友病治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における血友病治療薬のグローバル売上、2018年-2023年
・主要企業における血友病治療薬のグローバル売上シェア、2022年
・主要企業における血友病治療薬のグローバル販売量、2018年-2023年
・主要企業における血友病治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciences

*************************************************************

・調査・分析レポートの概要
血友病治療薬市場の定義
市場セグメント
世界の血友病治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の血友病治療薬市場規模
世界の血友病治療薬市場規模：2022年 VS 2029年
世界の血友病治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの血友病治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の血友病治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：血液製品、遺伝子組み換え製品
血友病治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：血友病A、血友病B
血友病治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別血友病治療薬市場規模 2022年と2029年
地域別血友病治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Bayer、 Pfizer、 Novo Nordisk、 Takeda Pharmaceutical、 CSL Behring、 Sanofi、 Octapharma、 Grifols、 BioMarin Pharmaceutical、 Roche、 Bio Products Laboratory (BPL)、 Kedrion Biopharma、 LFB Group、 HuaLan Bio、 Shanghai RAAS、 Gensciences
...

This research report provides a comprehensive analysis of the Hemophilia Medication market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Hemophilia Medication market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Hemophilia Medication, challenges faced by the industry, and potential opportunities for market players.
The global Hemophilia Medication market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Hemophilia Medication market presents opportunities for various stakeholders, including Hemophilia A, Hemophilia B. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Hemophilia Medication market. Additionally, the growing consumer demand present avenues for market expansion.
The global Hemophilia Medication market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Hemophilia Medication market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Hemophilia Medication market.
Market Overview: The report provides a comprehensive overview of the Hemophilia Medication market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Blood Products, Genetically Engineered Product), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Hemophilia Medication market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Hemophilia Medication market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Hemophilia Medication market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Hemophilia Medication market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Hemophilia Medication market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Hemophilia Medication market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Hemophilia Medication, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Hemophilia Medication market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Hemophilia Medication market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Blood Products
Genetically Engineered Product
Market segment by Application
Hemophilia A
Hemophilia B
Global Hemophilia Medication Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Bayer
Pfizer
Novo Nordisk
Takeda Pharmaceutical
CSL Behring
Sanofi
Octapharma
Grifols
BioMarin Pharmaceutical
Roche
Bio Products Laboratory (BPL)
Kedrion Biopharma
LFB Group
HuaLan Bio
Shanghai RAAS
Gensciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemophilia Medication, market overview.
Chapter 2: Global Hemophilia Medication market size in revenue and volume.
Chapter 3: Detailed analysis of Hemophilia Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemophilia Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hemophilia Medication capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Hemophilia Medication Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemophilia Medication Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemophilia Medication Overall Market Size
2.1 Global Hemophilia Medication Market Size: 2022 VS 2029
2.2 Global Hemophilia Medication Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Hemophilia Medication Sales: 2018-2029
3 Company Landscape
3.1 Top Hemophilia Medication Players in Global Market
3.2 Top Global Hemophilia Medication Companies Ranked by Revenue
3.3 Global Hemophilia Medication Revenue by Companies
3.4 Global Hemophilia Medication Sales by Companies
3.5 Global Hemophilia Medication Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hemophilia Medication Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hemophilia Medication Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hemophilia Medication Players in Global Market
3.8.1 List of Global Tier 1 Hemophilia Medication Companies
3.8.2 List of Global Tier 2 and Tier 3 Hemophilia Medication Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Hemophilia Medication Market Size Markets, 2022 & 2029
4.1.2 Blood Products
4.1.3 Genetically Engineered Product
4.2 By Type – Global Hemophilia Medication Revenue & Forecasts
4.2.1 By Type – Global Hemophilia Medication Revenue, 2018-2023
4.2.2 By Type – Global Hemophilia Medication Revenue, 2024-2029
4.2.3 By Type – Global Hemophilia Medication Revenue Market Share, 2018-2029
4.3 By Type – Global Hemophilia Medication Sales & Forecasts
4.3.1 By Type – Global Hemophilia Medication Sales, 2018-2023
4.3.2 By Type – Global Hemophilia Medication Sales, 2024-2029
4.3.3 By Type – Global Hemophilia Medication Sales Market Share, 2018-2029
4.4 By Type – Global Hemophilia Medication Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hemophilia Medication Market Size, 2022 & 2029
5.1.2 Hemophilia A
5.1.3 Hemophilia B
5.2 By Application – Global Hemophilia Medication Revenue & Forecasts
5.2.1 By Application – Global Hemophilia Medication Revenue, 2018-2023
5.2.2 By Application – Global Hemophilia Medication Revenue, 2024-2029
5.2.3 By Application – Global Hemophilia Medication Revenue Market Share, 2018-2029
5.3 By Application – Global Hemophilia Medication Sales & Forecasts
5.3.1 By Application – Global Hemophilia Medication Sales, 2018-2023
5.3.2 By Application – Global Hemophilia Medication Sales, 2024-2029
5.3.3 By Application – Global Hemophilia Medication Sales Market Share, 2018-2029
5.4 By Application – Global Hemophilia Medication Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Hemophilia Medication Market Size, 2022 & 2029
6.2 By Region – Global Hemophilia Medication Revenue & Forecasts
6.2.1 By Region – Global Hemophilia Medication Revenue, 2018-2023
6.2.2 By Region – Global Hemophilia Medication Revenue, 2024-2029
6.2.3 By Region – Global Hemophilia Medication Revenue Market Share, 2018-2029
6.3 By Region – Global Hemophilia Medication Sales & Forecasts
6.3.1 By Region – Global Hemophilia Medication Sales, 2018-2023
6.3.2 By Region – Global Hemophilia Medication Sales, 2024-2029
6.3.3 By Region – Global Hemophilia Medication Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Hemophilia Medication Revenue, 2018-2029
6.4.2 By Country – North America Hemophilia Medication Sales, 2018-2029
6.4.3 US Hemophilia Medication Market Size, 2018-2029
6.4.4 Canada Hemophilia Medication Market Size, 2018-2029
6.4.5 Mexico Hemophilia Medication Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Hemophilia Medication Revenue, 2018-2029
6.5.2 By Country – Europe Hemophilia Medication Sales, 2018-2029
6.5.3 Germany Hemophilia Medication Market Size, 2018-2029
6.5.4 France Hemophilia Medication Market Size, 2018-2029
6.5.5 U.K. Hemophilia Medication Market Size, 2018-2029
6.5.6 Italy Hemophilia Medication Market Size, 2018-2029
6.5.7 Russia Hemophilia Medication Market Size, 2018-2029
6.5.8 Nordic Countries Hemophilia Medication Market Size, 2018-2029
6.5.9 Benelux Hemophilia Medication Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Hemophilia Medication Revenue, 2018-2029
6.6.2 By Region – Asia Hemophilia Medication Sales, 2018-2029
6.6.3 China Hemophilia Medication Market Size, 2018-2029
6.6.4 Japan Hemophilia Medication Market Size, 2018-2029
6.6.5 South Korea Hemophilia Medication Market Size, 2018-2029
6.6.6 Southeast Asia Hemophilia Medication Market Size, 2018-2029
6.6.7 India Hemophilia Medication Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Hemophilia Medication Revenue, 2018-2029
6.7.2 By Country – South America Hemophilia Medication Sales, 2018-2029
6.7.3 Brazil Hemophilia Medication Market Size, 2018-2029
6.7.4 Argentina Hemophilia Medication Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Hemophilia Medication Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Hemophilia Medication Sales, 2018-2029
6.8.3 Turkey Hemophilia Medication Market Size, 2018-2029
6.8.4 Israel Hemophilia Medication Market Size, 2018-2029
6.8.5 Saudi Arabia Hemophilia Medication Market Size, 2018-2029
6.8.6 UAE Hemophilia Medication Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Hemophilia Medication Major Product Offerings
7.1.4 Bayer Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Hemophilia Medication Major Product Offerings
7.2.4 Pfizer Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Summary
7.3.2 Novo Nordisk Business Overview
7.3.3 Novo Nordisk Hemophilia Medication Major Product Offerings
7.3.4 Novo Nordisk Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.3.5 Novo Nordisk Key News & Latest Developments
7.4 Takeda Pharmaceutical
7.4.1 Takeda Pharmaceutical Company Summary
7.4.2 Takeda Pharmaceutical Business Overview
7.4.3 Takeda Pharmaceutical Hemophilia Medication Major Product Offerings
7.4.4 Takeda Pharmaceutical Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.4.5 Takeda Pharmaceutical Key News & Latest Developments
7.5 CSL Behring
7.5.1 CSL Behring Company Summary
7.5.2 CSL Behring Business Overview
7.5.3 CSL Behring Hemophilia Medication Major Product Offerings
7.5.4 CSL Behring Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.5.5 CSL Behring Key News & Latest Developments
7.6 Sanofi
7.6.1 Sanofi Company Summary
7.6.2 Sanofi Business Overview
7.6.3 Sanofi Hemophilia Medication Major Product Offerings
7.6.4 Sanofi Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.6.5 Sanofi Key News & Latest Developments
7.7 Octapharma
7.7.1 Octapharma Company Summary
7.7.2 Octapharma Business Overview
7.7.3 Octapharma Hemophilia Medication Major Product Offerings
7.7.4 Octapharma Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.7.5 Octapharma Key News & Latest Developments
7.8 Grifols
7.8.1 Grifols Company Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Hemophilia Medication Major Product Offerings
7.8.4 Grifols Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.8.5 Grifols Key News & Latest Developments
7.9 BioMarin Pharmaceutical
7.9.1 BioMarin Pharmaceutical Company Summary
7.9.2 BioMarin Pharmaceutical Business Overview
7.9.3 BioMarin Pharmaceutical Hemophilia Medication Major Product Offerings
7.9.4 BioMarin Pharmaceutical Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.9.5 BioMarin Pharmaceutical Key News & Latest Developments
7.10 Roche
7.10.1 Roche Company Summary
7.10.2 Roche Business Overview
7.10.3 Roche Hemophilia Medication Major Product Offerings
7.10.4 Roche Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.10.5 Roche Key News & Latest Developments
7.11 Bio Products Laboratory (BPL)
7.11.1 Bio Products Laboratory (BPL) Company Summary
7.11.2 Bio Products Laboratory (BPL) Business Overview
7.11.3 Bio Products Laboratory (BPL) Hemophilia Medication Major Product Offerings
7.11.4 Bio Products Laboratory (BPL) Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.11.5 Bio Products Laboratory (BPL) Key News & Latest Developments
7.12 Kedrion Biopharma
7.12.1 Kedrion Biopharma Company Summary
7.12.2 Kedrion Biopharma Business Overview
7.12.3 Kedrion Biopharma Hemophilia Medication Major Product Offerings
7.12.4 Kedrion Biopharma Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.12.5 Kedrion Biopharma Key News & Latest Developments
7.13 LFB Group
7.13.1 LFB Group Company Summary
7.13.2 LFB Group Business Overview
7.13.3 LFB Group Hemophilia Medication Major Product Offerings
7.13.4 LFB Group Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.13.5 LFB Group Key News & Latest Developments
7.14 HuaLan Bio
7.14.1 HuaLan Bio Company Summary
7.14.2 HuaLan Bio Business Overview
7.14.3 HuaLan Bio Hemophilia Medication Major Product Offerings
7.14.4 HuaLan Bio Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.14.5 HuaLan Bio Key News & Latest Developments
7.15 Shanghai RAAS
7.15.1 Shanghai RAAS Company Summary
7.15.2 Shanghai RAAS Business Overview
7.15.3 Shanghai RAAS Hemophilia Medication Major Product Offerings
7.15.4 Shanghai RAAS Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.15.5 Shanghai RAAS Key News & Latest Developments
7.16 Gensciences
7.16.1 Gensciences Company Summary
7.16.2 Gensciences Business Overview
7.16.3 Gensciences Hemophilia Medication Major Product Offerings
7.16.4 Gensciences Hemophilia Medication Sales and Revenue in Global (2018-2023)
7.16.5 Gensciences Key News & Latest Developments
8 Global Hemophilia Medication Production Capacity, Analysis
8.1 Global Hemophilia Medication Production Capacity, 2018-2029
8.2 Hemophilia Medication Production Capacity of Key Manufacturers in Global Market
8.3 Global Hemophilia Medication Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hemophilia Medication Supply Chain Analysis
10.1 Hemophilia Medication Industry Value Chain
10.2 Hemophilia Medication Upstream Market
10.3 Hemophilia Medication Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hemophilia Medication Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Hemophilia Medication in Global Market
Table 2. Top Hemophilia Medication Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Hemophilia Medication Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Hemophilia Medication Revenue Share by Companies, 2018-2023
Table 5. Global Hemophilia Medication Sales by Companies, (K Units), 2018-2023
Table 6. Global Hemophilia Medication Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Hemophilia Medication Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Hemophilia Medication Product Type
Table 9. List of Global Tier 1 Hemophilia Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hemophilia Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Hemophilia Medication Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Hemophilia Medication Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Hemophilia Medication Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Hemophilia Medication Sales (K Units), 2018-2023
Table 15. By Type - Global Hemophilia Medication Sales (K Units), 2024-2029
Table 16. By Application – Global Hemophilia Medication Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Hemophilia Medication Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Hemophilia Medication Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Hemophilia Medication Sales (K Units), 2018-2023
Table 20. By Application - Global Hemophilia Medication Sales (K Units), 2024-2029
Table 21. By Region – Global Hemophilia Medication Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Hemophilia Medication Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Hemophilia Medication Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Hemophilia Medication Sales (K Units), 2018-2023
Table 25. By Region - Global Hemophilia Medication Sales (K Units), 2024-2029
Table 26. By Country - North America Hemophilia Medication Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Hemophilia Medication Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Hemophilia Medication Sales, (K Units), 2018-2023
Table 29. By Country - North America Hemophilia Medication Sales, (K Units), 2024-2029
Table 30. By Country - Europe Hemophilia Medication Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Hemophilia Medication Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Hemophilia Medication Sales, (K Units), 2018-2023
Table 33. By Country - Europe Hemophilia Medication Sales, (K Units), 2024-2029
Table 34. By Region - Asia Hemophilia Medication Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Hemophilia Medication Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Hemophilia Medication Sales, (K Units), 2018-2023
Table 37. By Region - Asia Hemophilia Medication Sales, (K Units), 2024-2029
Table 38. By Country - South America Hemophilia Medication Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Hemophilia Medication Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Hemophilia Medication Sales, (K Units), 2018-2023
Table 41. By Country - South America Hemophilia Medication Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Hemophilia Medication Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Hemophilia Medication Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Hemophilia Medication Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Hemophilia Medication Sales, (K Units), 2024-2029
Table 46. Bayer Company Summary
Table 47. Bayer Hemophilia Medication Product Offerings
Table 48. Bayer Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Bayer Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Hemophilia Medication Product Offerings
Table 52. Pfizer Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Novo Nordisk Company Summary
Table 55. Novo Nordisk Hemophilia Medication Product Offerings
Table 56. Novo Nordisk Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Novo Nordisk Key News & Latest Developments
Table 58. Takeda Pharmaceutical Company Summary
Table 59. Takeda Pharmaceutical Hemophilia Medication Product Offerings
Table 60. Takeda Pharmaceutical Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Takeda Pharmaceutical Key News & Latest Developments
Table 62. CSL Behring Company Summary
Table 63. CSL Behring Hemophilia Medication Product Offerings
Table 64. CSL Behring Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. CSL Behring Key News & Latest Developments
Table 66. Sanofi Company Summary
Table 67. Sanofi Hemophilia Medication Product Offerings
Table 68. Sanofi Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Sanofi Key News & Latest Developments
Table 70. Octapharma Company Summary
Table 71. Octapharma Hemophilia Medication Product Offerings
Table 72. Octapharma Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Octapharma Key News & Latest Developments
Table 74. Grifols Company Summary
Table 75. Grifols Hemophilia Medication Product Offerings
Table 76. Grifols Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Grifols Key News & Latest Developments
Table 78. BioMarin Pharmaceutical Company Summary
Table 79. BioMarin Pharmaceutical Hemophilia Medication Product Offerings
Table 80. BioMarin Pharmaceutical Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. BioMarin Pharmaceutical Key News & Latest Developments
Table 82. Roche Company Summary
Table 83. Roche Hemophilia Medication Product Offerings
Table 84. Roche Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Roche Key News & Latest Developments
Table 86. Bio Products Laboratory (BPL) Company Summary
Table 87. Bio Products Laboratory (BPL) Hemophilia Medication Product Offerings
Table 88. Bio Products Laboratory (BPL) Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Bio Products Laboratory (BPL) Key News & Latest Developments
Table 90. Kedrion Biopharma Company Summary
Table 91. Kedrion Biopharma Hemophilia Medication Product Offerings
Table 92. Kedrion Biopharma Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Kedrion Biopharma Key News & Latest Developments
Table 94. LFB Group Company Summary
Table 95. LFB Group Hemophilia Medication Product Offerings
Table 96. LFB Group Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. LFB Group Key News & Latest Developments
Table 98. HuaLan Bio Company Summary
Table 99. HuaLan Bio Hemophilia Medication Product Offerings
Table 100. HuaLan Bio Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. HuaLan Bio Key News & Latest Developments
Table 102. Shanghai RAAS Company Summary
Table 103. Shanghai RAAS Hemophilia Medication Product Offerings
Table 104. Shanghai RAAS Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Shanghai RAAS Key News & Latest Developments
Table 106. Gensciences Company Summary
Table 107. Gensciences Hemophilia Medication Product Offerings
Table 108. Gensciences Hemophilia Medication Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 109. Gensciences Key News & Latest Developments
Table 110. Hemophilia Medication Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 111. Global Hemophilia Medication Capacity Market Share of Key Manufacturers, 2021-2023
Table 112. Global Hemophilia Medication Production by Region, 2018-2023 (K Units)
Table 113. Global Hemophilia Medication Production by Region, 2024-2029 (K Units)
Table 114. Hemophilia Medication Market Opportunities & Trends in Global Market
Table 115. Hemophilia Medication Market Drivers in Global Market
Table 116. Hemophilia Medication Market Restraints in Global Market
Table 117. Hemophilia Medication Raw Materials
Table 118. Hemophilia Medication Raw Materials Suppliers in Global Market
Table 119. Typical Hemophilia Medication Downstream
Table 120. Hemophilia Medication Downstream Clients in Global Market
Table 121. Hemophilia Medication Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Hemophilia Medication Segment by Type in 2022
Figure 2. Hemophilia Medication Segment by Application in 2022
Figure 3. Global Hemophilia Medication Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hemophilia Medication Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Hemophilia Medication Revenue, 2018-2029 (US$, Mn)
Figure 7. Hemophilia Medication Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Hemophilia Medication Revenue in 2022
Figure 9. By Type - Global Hemophilia Medication Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Hemophilia Medication Revenue Market Share, 2018-2029
Figure 11. By Type - Global Hemophilia Medication Sales Market Share, 2018-2029
Figure 12. By Type - Global Hemophilia Medication Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Hemophilia Medication Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Hemophilia Medication Revenue Market Share, 2018-2029
Figure 15. By Application - Global Hemophilia Medication Sales Market Share, 2018-2029
Figure 16. By Application - Global Hemophilia Medication Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Hemophilia Medication Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Hemophilia Medication Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Hemophilia Medication Revenue Market Share, 2018-2029
Figure 20. By Region - Global Hemophilia Medication Sales Market Share, 2018-2029
Figure 21. By Country - North America Hemophilia Medication Revenue Market Share, 2018-2029
Figure 22. By Country - North America Hemophilia Medication Sales Market Share, 2018-2029
Figure 23. US Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Hemophilia Medication Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Hemophilia Medication Sales Market Share, 2018-2029
Figure 28. Germany Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 29. France Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Hemophilia Medication Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Hemophilia Medication Sales Market Share, 2018-2029
Figure 37. China Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 41. India Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Hemophilia Medication Revenue Market Share, 2018-2029
Figure 43. By Country - South America Hemophilia Medication Sales Market Share, 2018-2029
Figure 44. Brazil Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Hemophilia Medication Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Hemophilia Medication Sales Market Share, 2018-2029
Figure 48. Turkey Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Hemophilia Medication Revenue, (US$, Mn), 2018-2029
Figure 52. Global Hemophilia Medication Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Hemophilia Medication by Region, 2022 VS 2029
Figure 54. Hemophilia Medication Industry Value Chain
Figure 55. Marketing Channels

※参考情報

血友病は、血液が適切に凝固しない遺伝性の疾患であり、主に遺伝的要因に起因します。この病気は血液中の特定の凝固因子が欠乏または異常であることによって引き起こされます。最も一般的なタイプは、血友病Aと血友病Bの二つで、前者は第VIII因子の欠乏、後者は第IX因子の欠乏によって引き起こされます。血友病の患者は、外傷や手術後、あるいは時には自然に出血する可能性が高く、そのため継続的な治療が必要です。

血友病の治療は、主に欠乏している凝固因子を補充する薬剤を使用することによって行われます。これにより、出血のリスクを低下させ、生活の質を向上させることが目的となります。血友病治療薬には、さまざまな種類があり、それぞれに特有の特徴があります。

まず第一に、血友病Aや血友病Bに対する補充療法について考えます。血友病Aの患者の場合、第VIII因子を補充するための医薬品が使用されます。これには、ポリペプチド製剤や、遺伝子組み換え技術を用いた製品が含まれます。後者は、ヒト細胞を用いて生成された第VIII因子が使用され、感染症のリスクを低く抑えることができるため、現代の治療においてはおおむね標準的な選択肢となっています。

一方、血友病Bの場合は、第IX因子の補充が必要です。これも遺伝子組み換えによって製造された製品が一般的です。しかし、最近では、これらの治療薬に加えて新しいアプローチも開発されています。たとえば、長時間作用型の凝固因子製剤が登場し、投与頻度を減少させることができるようになりました。これにより、患者の治療に対する負担が軽減され、自己管理がしやすくなるメリットがあります。

さらに、血友病の治療には、凝固因子の阻害剤に対する対抗薬を使用する場合もあります。これらは、患者が抗体を生成し、補充した凝固因子が効果を示さない場合に使用されます。このように、治療法は患者の個別のニーズに応じて多様化しており、より個別化された治療が可能となっています。

最近の研究では、血友病治療に関連する遺伝子治療も注目されています。遺伝子治療は、欠損している凝固因子を生成する遺伝子を体内に導入し、自発的にその因子を生成させようとするアプローチです。これにより、長期的には患者が外部からの治療を必要としなくなる可能性が期待されています。現在でも、臨床試験が進行中であり、将来的には血友病治療の新たなスタンダードとなるかもしれません。

また、血友病患者が日常生活をより快適に過ごせるようにするためには、教育や支援体制も充実させる必要があります。患者自身が自らの病気について理解し、緊急時の対処法を知っておくことは非常に重要です。そのためには、医療提供者による指導や、患者同士のサポートグループが有効とされています。

血友病治療薬の開発には、多くの課題も存在します。たとえば、薬剤の高コストや供給の安定性、遺伝子治療の倫理的な問題などが考えられます。これらの課題を克服していくことで、より多くの患者が快適に生活できる社会を実現することが求められています。

最後に、血友病の治療は、単に出血の頻度を減少させるだけでなく、患者が社会生活を営む上でのサポートをも含んでいます。医療技術の進歩とともに、血友病患者の生活の質の向上につながる新たな治療法が今後も登場することが期待されています。これにより、治療を受ける患者やその家族がより安定した生活を送れるようになることを願っています。血友病の治療薬は、その進化を続け、未来の患者に希望をもたらすことでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血友病治療薬のグローバル市場展望 2023年-2029年：血液製品、遺伝子組み換え製品(Hemophilia Medication Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

血友病治療薬のグローバル市場展望 2023年-2029年：血液製品、遺伝子組み換え製品

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp